BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 20653505)

  • 1. Proteomics uncovering possible key players in F508del-CFTR processing and trafficking.
    Gomes-Alves P; Penque D
    Expert Rev Proteomics; 2010 Aug; 7(4):487-94. PubMed ID: 20653505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unravelling druggable signalling networks that control F508del-CFTR proteostasis.
    Hegde RN; Parashuraman S; Iorio F; Ciciriello F; Capuani F; Carissimo A; Carrella D; Belcastro V; Subramanian A; Bounti L; Persico M; Carlile G; Galietta L; Thomas DY; Di Bernardo D; Luini A
    Elife; 2015 Dec; 4():. PubMed ID: 26701908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622.
    Norez C; Bilan F; Kitzis A; Mettey Y; Becq F
    J Pharmacol Exp Ther; 2008 Apr; 325(1):89-99. PubMed ID: 18230692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repair of CFTR folding defects with correctors that function as pharmacological chaperones.
    Loo TW; Clarke DM
    Methods Mol Biol; 2011; 741():23-37. PubMed ID: 21594776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70.
    Farinha CM; Nogueira P; Mendes F; Penque D; Amaral MD
    Biochem J; 2002 Sep; 366(Pt 3):797-806. PubMed ID: 12069690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signaling pathways of proteostasis network unraveled by proteomic approaches on the understanding of misfolded protein rescue.
    Gomes-Alves P; Neves S; Penque D
    Methods Enzymol; 2011; 491():217-33. PubMed ID: 21329803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correcting the F508del-CFTR variant by modulating eukaryotic translation initiation factor 3-mediated translation initiation.
    Hutt DM; Loguercio S; Roth DM; Su AI; Balch WE
    J Biol Chem; 2018 Aug; 293(35):13477-13495. PubMed ID: 30006345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topogenesis of cystic fibrosis transmembrane conductance regulator (CFTR): regulation by the amino terminal transmembrane sequences.
    Chen M; Zhang JT
    Biochemistry; 1999 Apr; 38(17):5471-7. PubMed ID: 10220334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Misfolding of the cystic fibrosis transmembrane conductance regulator and disease.
    Cheung JC; Deber CM
    Biochemistry; 2008 Feb; 47(6):1465-73. PubMed ID: 18193900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of Phe508 in the first nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator increases its affinity for the heat shock cognate 70 chaperone.
    Scott-Ward TS; Amaral MD
    FEBS J; 2009 Dec; 276(23):7097-109. PubMed ID: 19878303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect.
    Robert R; Carlile GW; Pavel C; Liu N; Anjos SM; Liao J; Luo Y; Zhang D; Thomas DY; Hanrahan JW
    Mol Pharmacol; 2008 Feb; 73(2):478-89. PubMed ID: 17975008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative differential proteomics of cystic fibrosis cell models by SILAC (stable isotope labelling in cell culture).
    Guerrera IC; Ollero M; Vieu DL; Edelman A
    Methods Mol Biol; 2011; 742():213-25. PubMed ID: 21547735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintaining low Ca2+ level in the endoplasmic reticulum restores abnormal endogenous F508del-CFTR trafficking in airway epithelial cells.
    Norez C; Antigny F; Becq F; Vandebrouck C
    Traffic; 2006 May; 7(5):562-73. PubMed ID: 16643279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones.
    Wang Y; Bartlett MC; Loo TW; Clarke DM
    Mol Pharmacol; 2006 Jul; 70(1):297-302. PubMed ID: 16624886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
    Kerem E
    Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis transmembrane conductance regulator (CFTR) and renal function.
    Stanton BA
    Wien Klin Wochenschr; 1997 Jun; 109(12-13):457-64. PubMed ID: 9261986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The DeltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR.
    Du K; Sharma M; Lukacs GL
    Nat Struct Mol Biol; 2005 Jan; 12(1):17-25. PubMed ID: 15619635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Base treatment corrects defects due to misfolding of mutant cystic fibrosis transmembrane conductance regulator.
    Namkung W; Kim KH; Lee MG
    Gastroenterology; 2005 Dec; 129(6):1979-90. PubMed ID: 16344066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Misprocessing of the CFTR protein leads to mild cystic fibrosis phenotype.
    Clain J; Lehmann-Che J; Duguépéroux I; Arous N; Girodon E; Legendre M; Goossens M; Edelman A; de Braekeleer M; Teulon J; Fanen P
    Hum Mutat; 2005 Apr; 25(4):360-71. PubMed ID: 15776432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defective formation of PKA/CnA-dependent annexin 2-S100A10/CFTR complex in DeltaF508 cystic fibrosis cells.
    Borthwick LA; Riemen C; Goddard C; Colledge WH; Mehta A; Gerke V; Muimo R
    Cell Signal; 2008 Jun; 20(6):1073-83. PubMed ID: 18346874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.